Key result
Fluvastatin fails to alter T-lymphocyte LDL receptor activity in patients with heterozygous familial hypercholesterolemia.
Why the study?
The effects of fluvastatin on LDL receptor activity in patients with heterozygous familial hypercholesterolemia were unclear.
Does fluvastatin 40 mg daily alter LDL receptor activity in stimulated T-lymphocytes in patients with heterozygous familial hypercholesterolemia?
Observational (n=34)
Does fluvastatin 40 mg daily alter LDL receptor activity in stimulated T-lymphocytes in patients with heterozygous familial hypercholesterolemia?
Fluvastatin treatment for 12 weeks did not significantly change LDL receptor activity in stimulated T-lymphocytes of patients with heterozygous familial hypercholesterolemia, suggesting either a different primary response mechanism or a lack of extrahepatic effect.
Answers are grounded in this paper and cite their sources.
Does not support guiding fluvastatin therapy by T-lymphocyte LDL receptor activity in heterozygous FH; leaves open alternative mechanisms.
To test the effects of fluvastatin on low-density lipoprotein (LDL) receptor activity in patients with heterozygous familial hypercholesterolemia, the authors measured LDL receptor activity in stimulated T-lymphocytes prepared from 34 patients before and after treatment with 40 mg fluvastatin daily for 12 weeks. Maximally induced pretreatment LDL receptor activities did not correlate with pretreatment plasma cholesterol levels or with changes in plasma cholesterol levels during treatment, and there were no significant changes in LDL receptor activity during treatment. Barring methodological problems, two explanations are possible. Insofar that LDL receptor activity in lymphocytes reflects LDL receptor activity in the liver, the results suggest that the primary response to treatment with fluvastatin in heterozygous familial hypercholesterolemia (FH) patients is not enhanced LDL receptor activity. Alternatively, fluvastatin increases LDL receptor activity in hepatocytes but has little effect on receptor-dependent lipoprotein catabolism in extrahepatic tissues in vivo.
No takes yet. Share an insight, caveat, or question.
Raungaard et al. (2000) conducted an observational in Heterozygous familial hypercholesterolemia (n=34). Fluvastatin vs. Pretreatment baseline was evaluated on LDL receptor activity in stimulated T-lymphocytes (p=not significant). Fluvastatin produced no significant changes in LDL receptor activity in stimulated T-lymphocytes from patients with heterozygous familial hypercholesterolemia.
Synapse has enriched 10 related papers. Consider them for comparative context: